Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections

Abstract

Despite significant research efforts aimed at understanding the neurobiological underpinnings of psychiatric disorders, the diagnosis and the evaluation of treatment of these disorders are still based solely on relatively subjective assessment of symptoms. Therefore, biological markers which could improve the current classification of psychiatry disorders, and in perspective stratify patients on a biological basis into more homogeneous clinically distinct subgroups, are highly needed. In order to identify novel candidate biological markers for major depression and schizophrenia, we have applied a focused proteomic approach using plasma samples from a large case-control collection. Patients were diagnosed according to DSM criteria using structured interviews and a number of additional clinical variables and demographic information were assessed. Plasma samples from 245 depressed patients, 229 schizophrenic patients and 254 controls were submitted to multi analyte profiling allowing the evaluation of up to 79 proteins, including a series of cytokines, chemokines and neurotrophins previously suggested to be involved in the pathophysiology of depression and schizophrenia. Univariate data analysis showed more significant p-values than would be expected by chance and highlighted several proteins belonging to pathways or mechanisms previously suspected to be involved in the pathophysiology of major depression or schizophrenia, such as insulin and MMP-9 for depression, and BDNF, EGF and a number of chemokines for schizophrenia. Multivariate analysis was carried out to improve the differentiation of cases from controls and identify the most informative panel of markers. The results illustrate the potential of plasma biomarker profiling for psychiatric disorders, when conducted in large collections. The study highlighted a set of analytes as candidate biomarker signatures for depression and schizophrenia, warranting further investigation in independent collections.

Monocyte and microglial activation in patients with mood-stabilized bipolar disorder

“…In a multianalyte profiling study of plasma from patients with schizophrenia and major depression, MMPs and TIMPs emerged as significant markers discriminating patients from controls. 49 Our results indicate that serum TIMPs do not differentiate patients with moodstabilized bipolar disorder from healthy controls.…”

Wound Fluid Diagnostics in Diabetic Foot Ulcers

“…However, due to complex disease pathologies and aetiological heterogeneity, it turns out that standalone markers are rather unlikely to be specific or else applicable on a wide-scale and a whole set of candidate markers are considered to be more promising e.g. as demonstrated by Domenici et al (Domenici et al 2010). According to Yager et al there are as yet no accepted biomarkers, which allow the evaluation of the wound status and this critically hampers the improvement of appropriate treatments and effective therapies.…”

Old Obstacles on New Horizons: The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research

“…But each also remains curiously under-represented in mainstream GxE research today. This is despite evidence to suggest they may serve a functional purpose as biomarkers of environmentally-induced pathogenesis, susceptibility, illness progression and treatment outcome [146][147][148][149][150][151][152] . Despite these documented examples, each discipline also faces thematic questions about how to achieve methodological best practice, given their various respective constraints 147,153,154 .…”